Updated press release: Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China
(Updated press release with information about transaction advisor) · IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 · If exercised, the license has a potential value of up to USD 100 million in development and commercial milestones, in addition to double-digit royalties · The parties will negotiate a full License Agreement based on pre-agreed terms and principles in the Option Agreement Oslo, Norway 8 January 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company